Key Findings
A research team comprising experts from DZNE, the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, and partners in Bonn, London, and Portugal, has successfully tested a new ASO-based approach for treating Spinocerebellar Ataxia Type 3 (SCA3). The most effective ASOs tested reduced the amount of toxic Ataxin-3 by approximately 90% in lab-cultured human neurons. Crucially, the treatment preserved the normal form of the protein, achieving a level of specificity not found in previous ASO-based therapeutic attempts.
Technical Details
The therapy targets the production chain of proteins by binding to mRNA molecules. The ASOs are designed to trigger the degradation of mRNA specifically associated with the disease-causing gene, thereby reducing the production of the harmful Ataxin-3 protein. To achieve this precision, the researchers analyzed the genomes of 79 individuals with SCA3 to identify Single Nucleotide Polymorphisms (SNPs).
- Mechanism: ASOs identify subtle SNP differences between the disease-causing gene copy and the healthy counterpart.
- Selectivity: By targeting these SNPs, the ASOs preferentially promote the degradation of mutant mRNA while leaving the healthy mRNA intact.
- Outcome: This allows the cell to continue producing the normal Ataxin-3 protein, which performs essential cellular functions.
Background & Context
SCA3, also known as Machado-Joseph disease, is a severe inherited neurodegenerative disorder characterized by difficulties in speech, walking, and eye movements. The disease is triggered by a genetic mutation where a specific stretch of DNA is repeated too many times, resulting in a toxic form of the Ataxin-3 protein. While humans typically have two copies of this gene, SCA3 usually involves only one mutated copy.
Significance & Outlook
The study, published in Science Translational Medicine, addresses a major limitation of previous ASO therapies, which often caused collateral damage by attacking healthy proteins alongside toxic ones. The team now intends to optimize the most promising ASOs and conduct further studies on efficacy and safety. The long-term objective is to move toward human clinical trials, though researchers note this process will take time.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
